The asx does not rate medtech like the NASDAQ does.I am into AVR as well and they are going to the NASDAQ in the next 6 months as per their agm in order to raise more money and not to be confined by a 15% asx ruling. If they gain 5% of the $10b market they are in and be priced as per their rivals they would have a SP of $600. Presently $19. They like EYE have a better product than the market leader Edwards science as per the data.
The asx does not rate medtech like the NASDAQ does.I am into AVR...
-
- There are more pages in this discussion • 199 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.005(2.04%) |
Mkt cap ! $56.06M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.8¢ | 24.0¢ | $61.84K | 254.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 353553 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 254871 | 2 |
View Market Depth
| Last trade - 15.54pm 30/07/2024 (20 minute delay) ? |
| EYE (ASX) Chart |